Showing results 1 - 10 of 13
Vol. 43, Issue 10, Pages 1420-1427
Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to negotiate rebates and lead to higher…
Vol. 5, Issue 6, Pages e242342
Recent efforts to control spending, including accountable care organizations, value-based payment, and high-deductible health plans, have emphasized optimizing patterns of health…
The Inflation Reduction Act (IRA) of 2022 is the most significant reform to US prescription drug pricing in two decades and the first expected to result in a net reduction in…
Vol. 5, Issue 2, Pages e240193
The growth in spending on health care has slowed over the last decade, easing fears that Medicare would devour the federal budget, create crippling federal deficits, and cause…
The Inflation Reduction Act (IRA) requires Medicare to negotiate lower prices for some medicines with high Medicare spending. Using historical data from public and proprietary…
Notwithstanding concerns about staffing levels and burnout in health care, federal wage and employment data does not support the suggestion that a Covid-19 pandemic-related spike…
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single…
Vol. 4, Issue 10
The debate around prescription drug measures in the recently passed U.S. Inflation Reduction Act (IRA), which limit some patients’ out-of-pocket costs, has not fully addressed…
Vol. 37, Issue 2, Pages 99-122
The United States spends substantially more on health care than most developed countries, yet leaves a greater share of the population uninsured. We argue that incremental…
Vol. 4, Issue 2, Pages e230187
The US spends substantially more on health care per capita than other high-income countries yet leaves a greater share of the population uninsured. Traditional economic models—and…